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Bone quality and 
osteoporosis therapy
Qualidade óssea e tratamento da osteoporose
Regina Matsunaga Martin1, Pedro Henrique S. Correa1 
SUMMARY
Although BMD measured by DXA is a useful clinical tool for osteoporosis diagnosis, changes 
resulting from osteoporosis treatment only partially explain the observed reduction in frac-
tures. Several other bone properties that influence its resistance to fractures and explain this 
discrepancy have been defined as “bone quality”. Bone quality is determined by its structural 
and material properties and orchestrated by bone turnover, a continuous process of renewal 
through which old or damaged bone is replaced by a mechanically healthy bone and calcium 
homeostasis is maintained. Bone structural properties include its geometry (size and shape) 
and microarchitecture (trabecular architecture and cortical porosity), while bone material pro-
perties include its mineral and collagen composition as well as microdamage and its repair. This 
review aims to update concepts surrounding bone quality and how drugs employed to treat 
osteoporosis might influence them. Arq Bras Endocrinol Metab. 2010;54(2):186-99
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SUMÁRIO
Embora a DMO, medida por DEXA, seja um recurso clínico útil para o diagnóstico da osteo-
porose, mudanças resultantes do tratamento da osteoporose explicam apenas parcialmente a 
redução de fraturas. As demais propriedades ósseas que influenciam sua resistência a fraturas, 
que não se referem à massa óssea e explicam a discrepância entre os valores de DMO e o risco 
de fratura, têm sido definidas como “qualidade óssea”. A qualidade óssea é determinada por 
suas propriedades estruturais e materiais e orquestrada pela remodelação óssea, um processo 
contínuo de renovação por meio do qual o osso velho ou danificado é substituído por um osso 
mecanicamente saudável e a homeostase do cálcio é mantida. As propriedades estruturais ós-
seas incluem suas geometria (tamanho e formato) e microarquitetura (arquitetura trabecular e 
porosidade cortical), enquanto as propriedades materiais referem-se à sua composição mineral 
e colágena assim como ao microdano e seu reparo. O objetivo desta revisão é uma atualização 
sobre qualidade óssea e como os medicamentos empregados no tratamento da osteoporose 
podem modificá-la. Arq Bras Endocrinol Metab. 2010;54(2):186-99
Descritores
Qualidade óssea; remodelação; força; fratura; osteoporose; tratamento
INTRODUCTION
Osteoporosis is a bone disease characterized by low bone strength leading to increasing susceptibility 
to bone fracture. The capacity of bone to resist mecha-
nical forces and fractures depends not only on the quan-
tity of bone tissue but also on its quality.
The amount of bone tissue is in part evaluated by 
measuring bone mineral density (BMD) using dual X-
ray absorptiometry (DXA). BMD is currently the most 
important determinant of bone strength and fracture 
risk (1), nevertheless it does not entirely predict the 
risk of fracture and changes in BMD account for only 
a portion of the fracture risk reduction observed with 
osteoporosis therapies. Older people can have up to ten-
fold increased 10-year fracture risk in comparison with 
younger individuals with the same BMD (2). Thus, in 
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individuals with comparable BMD, fracture risks are 
not the same. In addition, more than 50% of all frac-
tures occur in women with osteopenia, as defined by a 
-2.5 < BMD T score ≤ -1; at-risk women in this group 
will not be detected by applying the World Health Or-
ganization BMD definition of osteoporosis (3).
Changes in BMD associated with antiresorptive 
treatments account for less than 40% of its effect in re-
ducing vertebral fracture risk (4,5) demonstrating that 
changes in BMD with osteoporosis treatments only 
partially explain fracture risk reduction and that addi-
tional independent factors may contribute to the clini-
cal efficacy of these therapies.
The term “bone quality” was therefore introduced 
to refer to the combination of factors that influence 
fracture risk but are not related to bone mass (6,7).
BONE QUALITY
Bone quality is determined by structural and material 
properties that are influenced by bone turnover rate. 
Bone turnover or remodeling is a continuous process 
of bone renewal in which old or damaged bone is re-
sorbed and new bone is formed to replace it producing 
a mechanically sound bone and maintaining calcium 
homeostasis. Bone structural properties include its 
geometry (size and shape) and microarchitecture (tra-
becular/cancellous architecture and cortical thickness/
porosity), while bone material properties include its 
mineral and collagen composition as well as microdam-
age and its repair (Figure 1).
While there is no precise measure of bone strength, 
BMD has been widely used as a noninvasive surrogate 
of this parameter as well as an accurate predictor of frac-
ture risk. Besides using DXA, BMD can be measured 
by quantitative computer tomography (QCT) reflect-
Microarchitecture Geometry (shape 
and size)
Microdamage and 
repair
Matrix and mineral 
composition
Mineralization
Bone remodeling
Balance of formation/
resorption
Figure 1. Determinants of bone quality.
ing volumetric BMD instead of an areal projection and 
therefore allowing the determination of the actual vol-
umetric density of bone independent of its size.
However, using bone biopsy or autopsy specimens, 
a number of approaches have been developed provid-
ing better comprehension of how bone quality contrib-
utes to bone strength in untreated and treated disease 
states. The most popular of these approaches is histo-
morphometry, but newer imaging techniques such as 
microcomputed tomography (µCT) and magnetic res-
onance microimaging (µMRI) allow the measurement 
of three-dimensional (3D) trabecular microarchitecture 
in bone specimens in a non-destructive way. Although 
MRI and µCT analysis are reliable, they should be 
preferably used in combination to obtain valid conclu-
sions. Nevertheless, the use of these techniques is still 
restricted due to their limited availability, high cost and 
relatively high radiation exposure.
Bone turnover or remodeling
Bone turnover coordinates the various factors that con-
tribute to bone quality (Figure 1). The balance between 
bone resorption and formation is the key component in 
preserving bone quality, repairing microarchitectural 
damage, maintaining BMD and reducing fracture risk.
Accelerated bone turnover leads to the irreversible 
loss of some trabeculae, resulting in weaker bone and 
increased fracture risk. Since it is not possible to rou-
tinely assess trabecular connectivity in patients with os-
teoporosis, bone turnover is most commonly assessed 
in clinical practice by the measurement of biochemical 
markers of bone turnover.
Detectable in blood or urine, bone turnover mark-
ers are products of osteoblasts/osteocytes and osteo-
clasts type I collagen breakdown reflecting bone for-
mation and bone resorption, respectively. For instance, 
CTx (bone type I collagen C-telopeptide) is a product 
of collagen degradation and therefore mirrors bone re-
sorption; elevated CTx levels generally mean acceler-
ated bone turnover.
Bone markers are also helpful for assessing response 
to antiresorptive therapy; they are commonly reduced 
after one (resorption markers) to four (formation mark-
ers) months of treatment. However, there is consider-
able intra- and inter-individual variability, and levels may 
be affected by diet and the circadian rhythm. Neverthe-
less, the measurement of bone turnover markers in addi-
tion to BMD has been proposed as a more effective sur-
rogate for predicting fracture risk than BMD alone (8).
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Bone turnover can also be assessed by bone histo-
morphometry using tetracycline labeling prior to biop-
sy. The extent of tetracycline-labeled surfaces indicates 
bone turnover, provided that bone remodeling is in a 
steady state and that bone resorption and formation are 
coupled.
Histomorphometry consists of the quantitative 
analysis of bone resorption parameters, formation and 
structure on histological sections, and is largely con-
sidered the gold standard for assessing bone turnover 
since it is the only available method for direct in situ 
analysis of bone cells and their activity. In addition, this 
technique can assess 2D bone microarchitecture allow-
ing measurements such as thickness and connectivity of 
trabeculae. Moreover, computerized analysis of biopsy 
specimens can assess resorption cavity characteristics in 
quantitative terms such as mean and maximum eroded 
depth, and eroded area. Nevertheless, bone turnover 
in iliac crest biopsies may not reflect changes at other 
skeletal sites and the invasive nature of this procedure 
may pose as a disadvantage to its widespread use (6).
Biochemical markers and histomorphometry differ 
in their assessment of bone turnover particularly in re-
spect to the degree of suppression of bone turnover by 
anti-resorptive agents, which is generally greater when 
assessed by the latter technique.
Bone geometry
The external diameter and cortical thickness of bone 
play crucial roles in determining bone strength. Bone 
geometry takes into account the distribution of bone 
mass and the ability of bone to resist torsion and bend-
ing (i.e., the wider the external diameter of a cylinder, 
the higher its resistance to bending). Therefore, for the 
same areal BMD, a wider bone has greater bending 
strength and axial strength because its mass is distrib-
uted further away from the center (Figure 2A).
Considerable evidence indicates that age-related de-
clines in the material properties of bone tissue are ac-
companied by a redistribution of cortical and trabecu-
lar bone. Specifically in the appendicular skeleton these 
changes involve endosteal resorption within the bone 
combined with periosteal apposition on the external sur-
face. This leads to an age-related increase in the diameter 
of long bones but a decrease in cortical thickness. This 
increase in the outer diameter helps to maintain the re-
sistance to bending and torsional loads. For many years, 
it has been suggested that men undergo this pattern of 
favorable geometric adaptation to a greater extent than 
women, providing one possible explanation for lower 
fracture rates in elderly men than women. However, re-
cent data has shown that both men and women undergo 
favorable geometric changes with aging (Figure 2B).
Figure 2. Influence of bone geometry on bone strength. A. for the same areal BMD, bone C has progressively greater bending strength and axial strength 
than bone B and bone A because the mass of bone C is distributed further away from the center – adapted from Bouxsein (63). B. Sex and aging differences 
in periosteal apposition and endocortical resorption in tubular bones. Adapted from Seeman (64).
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Bone microarchitecture
Changes in bone microarchitecture make an important 
contribution to bone strength that may not always be 
captured by bone mineral density measurements. Corti-
cal and cancellous architecture are both important in this 
respect. In cancellous bone, the number and thickness 
of trabeculae and their connectivity and orientation (an-
isotropy) contribute to bone strength, whilst in cortical 
bone its width and porosity are the main determinants.
Altered bone microarchitecture in untreated and 
treated disease states result from underlying changes in 
bone remodeling. High turnover states and increased os-
teoclast activity predispose to trabecular penetration, loss 
of connectivity, cortical thinning and increased cortical 
porosity, whereas low bone turnover states and reduced 
bone formation are associated with trabecular thinning 
and relative preservation of bone micro architecture.
Although some of these architectural features can 
be assessed by bone histomorphometry, more sophis-
ticated methods have now been developed that enable 
3D visualization and quantification.
The development of µCT scanning has enabled 3D 
evaluation of trabecular bone specimens at resolutions 
of 14-50 µm. With the use of µCT, bone volume (BV), 
trabecular number and thickness, and connectivity can 
be assessed. Strain on bone tissue can be measured by 
comparing structural elements with and without me-
chanical load. This technique is also potentially useful for 
studying molecular aspects of bone physiology as it can 
be performed at low temperatures, preserving RNA and 
therefore allowing the investigation of interactions be-
tween genetic profiles and biomechanical properties (6).
Microfinite element analysis by combining bone 
geometry with material characteristics to predict bone 
strength is a promising technique for fracture assess-
ment based on the calculation of the mechanical prop-
erties of trabecular sites from high-resolution images. 
The combined use of these two methods provided an 
in vivo assessment of apparent BV to total volume (BV/
TV) and quantified changes in horizontal elements of 
trabecular bone of the distal radius in postmenopausal 
women in terms of both structure and strength (6).
Finally, noninvasive, nonionizing high-resolution 
MRI can be used to evaluate trabecular bone. It has 
been employed to compare the trabecular structure of 
the calcaneus in women with and without hip fractures 
related to osteoporosis, allowing clear distinction be-
tween the two groups (9). More recently, the effects of 
calcitonin on parameters of trabecular microarchitecture 
were analyzed comparing both noninvasive MRI at mul-
tiple skeletal sites (radius, hip and calcaneous) and µCT/
histomorphometry acquired by iliac crest bone biopsy, in 
the QUEST (Qualitative Effects of Salmon-Calcitonin 
Treatment) trial. Although the results supported the use 
of MRI for assessment of trabecular microarchitecture in 
clinical research trials, the authors have highlighted site-
specific differences in response to antiresorptive thera-
pies and the need for sufficiently large sampling in order 
to reliably assess bone architecture (10).
Bone matrix composition
Bone matrix has essentially two constituents, mineral 
and collagen. The majority of evidence suggests that in 
normal bone the mineral provides stiffness and strength 
whereas collagen affords bone its ductility and ability to 
absorb energy (toughness) before fracturing.
Bone collagen is continuously renewed and its fi-
bers are stabilized posttranslationally through enzy-
matic cross-linking (pyridinoline and deoxypyridino-
line), non-enzymatic glycation generating AGEs (aged 
glycation product ends) such as pentosidine, and 
β-isomerization of the CTx epitope.
The ratio of pyridinoline/deoxypyridinoline (PYD/
DPD) has been shown to be positively associated with 
strength and stiffness in bone, but appears to have 
little correlation with toughness. Non-enzymatic col-
lagen cross-links (AGEs) make the tissue more brittle 
and susceptible to fractures. In vitro studies of fetal bo-
vine cortical bone have recently shown that changes in 
cross-link (PYD, DPD and AGEs) and in the degree of 
β-isomerization of carboxy telopeptide of type I colla-
gen accompany changes in bone mechanical properties 
resultant from aging (11).
The excess of AGEs leads to a decrease in tough-
ness and strength due to increased stiffness. Moreover, 
AGE-receptors present on certain cells (osteoblasts, for 
instance) may downregulate these cells. Interestingly, 
AGEs are increased in diabetes and may participate in the 
accelerated aging experienced by diabetic subjects (12).
CTx originates from recently synthesized type I col-
lagen as αα CTx and undergoes isomerization generat-
ing ββ CTx, which is released from aged type I collagen. 
Therefore, the assessment of αα and ββ CTx fragments 
by enzyme-linked immunosorbent assay reflects the age 
of endogenous bone collagen. The calculated αα/ββ 
CTx ratio in urine samples reflects mean bone collagen 
age and can be used as an index of bone matrix qual-
ity (13) (Figure 3). In agreement with this concept, it 
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scopic techniques. The degree of mineralization is cap-
tured by BMD measurements but its contribution, in 
relation to other factors influencing BMD, cannot be 
directly deduced.
Microdamage
Bone undergoes repeated cyclic loading and the result-
ing fatigue damage in bone matrix is expressed through 
microcracks or microdamage. Microdamage is gener-
ally defined as linear cracks detectable by light micros-
copy, and although the optimal method to quantify 
microdamage in bone is under debate, numerous stud-
ies have now shown that the accumulation of damage 
weakens the bone. Moreover, it appears that micro-
damage triggers remodeling, presumably to repair the 
damaged tissue (15). On the other hand, accumulation 
of microdamage may result from increased mineraliza-
tion secondary to suppression of remodeling, making 
the bone more brittle.
There is ongoing debate regarding the optimal level 
of bone turnover to prevent architectural deterioration 
while preserving the ability of bone to maintain calcium 
homeostasis, respond to altered mechanical loading, 
and to repair microdamage. The role of microdamage 
in age-related fragility fractures has yet to be estab-
lished. Microdamage accumulation has been proposed 
to be a factor that may contribute to increased skeletal 
fragility with age (16).
Techniques to detect microcracks require expensive 
technologies and training. Most data have been ob-
tained in animal models, and the applicability of some 
experimental results to the humans remains unclear. 
Studying microdamage in humans, specifically to de-
termine the impact of bone drugs, relies on iliac crest 
bone biopsies, which may not be appropriate because 
of the low numerical crack density on this site in com-
parison to others. Noninvasive techniques need to be 
developed to improve assessment of microdamage in 
vivo (17).
EFFECTS OF OSTEOPOROSIS MEDICATIONS ON 
BONE QUALITY
Drugs for osteoporosis treatment can be classified in 
two groups: antiresorptive or stimulating of bone for-
mation. However, it is increasingly clear that they act 
not only by improving BMD but also by increasing 
bone strength, modifying bone quality, and therefore 
reducing the risk of fracture.
Young bone Aged bone Old bone
High
Bone quality
+
-
Medium
Endogenous 
bone age
αα/ββ ratio in 
urine
Low
Figure 3. Schematic overview of the bone collagen age profile measured as 
the ratio between ααCTx and ββCTx. Adapted from Leeming and cols. (13).
has been shown that the mean age of bone assessed by 
αα/ββ CTx is higher in accelerated bone turnover (tra-
becular bone) and conversely lower in reduced bone 
turnover (cortical bone).
Mineralization
Mineralization of bone matrix consists of two succes-
sive steps. Primary mineralization occurs when the new 
collagen matrix begins to mineralize quickly and rep-
resents 50% to 60% of the mineralization maximum. 
Subsequently, the rate of mineralization slows down 
and secondary mineralization proceeds for a number 
of years. Typically, mineralization stabilizes around 90% 
to 95% of maximum. The degree of secondary miner-
alization is dependent on bone turnover; when this is 
low, there is more time for mineralization to proceed 
whereas in high turnover states, recently formed bone 
is removed before there is time for appropriate second-
ary mineralization.
As mineralization increases, the tissue becomes more 
brittle and requires less energy to fracture. Therefore, 
it is possible for a bone that is hypermineralized to be 
more fragile than a bone with a lower degree of miner-
alization. This effect may partially explain the findings 
of Riggs and cols. (14), who demonstrated that despite 
dramatic increases in BMD with fluoride treatment 
there was a significant increase in the number of pa-
tients with nonvertebral fractures in the fluoride group 
as compared with placebo. Conversely, when bone re-
sorption begins before completion of mineralization, 
a cumulative deficit in mineralization arises leading to 
decreased bone stiffness and strength.
The degree of mineralization and its distribution 
throughout bone can be measured ex vivo by several 
methods including microradiography, quantitative 
back-scattered electron imaging (qBEI) and spectro-
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Bisphosphonates (BPs)
Bisphosphonates (BPs) have great affinity for bone min-
eral and inhibitory effects on osteoclasts. The attach-
ment of BPs to crystalline hydroxyapatite is determined 
by their structure, mainly the P–C–P configuration. Ni-
trogen-containing bisphosphonates have become the 
standard of care for osteoporosis. Current oral BPs are: 
alendronate (daily or weekly dosing), risedronate (daily 
or weekly dosing) and ibandronate (monthly dosing) 
whereas intravenous regimens are available with pami-
dronate and zoledronic acid (quarterly or yearly) (18).
Besides significantly increase BMD in patients with 
osteoporosis, BPs also act by modifying bone quality to 
improve bone strength. Although it is difficult to assess 
the actions of BPs on bone quality in general practice, ev-
idence in that direction has accumulated in recent years.
Effects on bone mineralization
BPs decrease bone turnover and increase the duration 
of the secondary mineralization, thus improving the 
degree of mineralization. Boivin and cols. (19), treating 
postmenopausal women with osteoporosis with three-
year alendronate therapy, have shown an increase in 
mean mineralization at the iliac bone of approximately 
11% both in cancellous and cortical bone. Further, Bo-
rah and cols. (20), using µCT to assess biopsies from 
patients at baseline and after 3 and 5 years of risedro-
nate therapy, showed an increased homogeneity of 
mineralization. There was no significant difference in 
average or homogeneity mineralization values between 
3 and 5 years of risedronate therapy, neither hypermin-
eralization of the bone matrix was observed (21). 
Moreover, Recker and cols. (22) have shown that an-
nual IV administration of zoledronic acid during three 
years is effective in reducing bone remodeling and pre-
serving bone structure in postmenopausal women with 
osteoporosis. However, differences between zoledronic 
acid and oral BPs on mineralization have been verified 
as highlighted by Ebeling and Burr (23): zoledronic 
acid stimulates osteoblast activity resulting in acceler-
ated mineral apposition and increases bone volume but 
not secondary mineralization.
Role in microdamage
Bone remodeling aims to repair fatigue microdamage, 
nevertheless an excessive reduction of bone turnover 
may result in inadequate microdamage repair leading to 
a fracture. Animal bones overtreated with BPs exhibit 
suppressed trabecular bone turnover associated with 
increased vertebral strength, even with significant mi-
crodamage accumulation and reduced intrinsic energy 
absorption capacity (toughness) (24,25).
The mechanism of bisphosphonate-induced micro-
damage accumulation has not been fully established. 
BPs suppress turnover, reducing both targeted and sto-
chastic remodeling, and allowing microdamage to per-
sist for longer in comparison to untreated bone. More, 
increased mineralization and increased tissue homoge-
neity, both of which resultant from BP treatment, are 
permissive to the formation and accumulation of mi-
crodamage (26).
Action on type I collagen
Limited data is available concerning BP effects on the 
organic component of bone.
Saito and cols. (27) and Allen and cols. (28) have 
documented changes in enzymatic (PYD/DPD), non-
enzymatic cross-linking (AGEs) and collagen isomeri-
zation of the organic matrix in bisphosphonate-treated 
animals. Following treatment with a wide range of BP 
doses, the ratio PYD/DPD in the trabecular bone of 
lumbar vertebrae was significantly increased compared 
to vehicle-treated animals as well as the level of pento-
sidine (AGEs) in a dose-dependent fashion; conversely, 
the ratio of αα/ββ CTx was decreased when compared 
to untreated animals.
In human bone, pentosidine markedly increases 
with age, and its content in bone from patients with 
hip fracture is significantly higher than that of non-frac-
tured age-matched controls (29).
As the organic matrix is known to contribute to bio-
mechanical properties, these data suggest that changes 
in the non-mineral component with BP treatment may 
influence mechanical properties and therefore fracture 
risk. However, changes in the organic matrix may have 
some effect on tissue strength and stiffness, even if 
these properties are predominantly determined by min-
eralization.
Effects on bone geometry and microarchitecture
Each of the changes obtained with BPs treatment has a 
significant effect on material-level biomechanical prop-
erties, independent of changes in bone mass, but their 
specific individual contribution is difficult to assess ex-
perimentally. Probably, effects on bone mineralization 
and collagen cross-linking tend to increase bone stiff-
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ness and strength, whereas the increased microdamage 
tends to decrease both. The relevance of these changes 
remains enigmatic, however, considering that BPs also 
modify bone geometry and microarchitecture.
In this way, Davison and cols. (30) reviewed reports 
of reduced cortical porosity following treatment with 
BP and changes in parameters of trabecular 3D archi-
tecture after one-year risedronate therapy assessed by 
µCT. In the placebo group, bone volume, trabecular 
number and trabecular connectivity decreased whereas 
no such deterioration was observed in the risedronate 
group, with similar results even after 3 years of risedro-
nate therapy.
In the DIVA (Dosing IntraVenous Administra-
tion) study, conducted in postmenopausal women, 
around 12 mg in a year of IV ibandronate provided 
significantly greater gains in BMD than 2.5 mg daily 
oral ibandronate, with equivalent efficacy and similar 
safety. Following 2 years of ibandronate treatment, tra-
becular bone maintained its normal lamellar structure 
with no evidence of woven bone, marrow fibrosis, cel-
lular toxicity, or other qualitative abnormalities. His-
tomorphometric analysis of 89 transiliac bone biopsies 
demonstrated normal micro-structure of newly formed 
bone with normal mineralization and reduced remod-
eling after oral or IV ibandronate (31). Because the IV 
ibandronate regimen in DIVA has an annual cumulative 
exposure similar to the 150 mg monthly oral ibandro-
nate, it is possible that the positive histomorphometric 
and bone safety profiles observed may also reflect the 
effects of its current oral use.
To date, it appears these macro-level changes drive 
the anti-fracture efficacy of BPs, and can adequately 
compensate for reduced material properties. Neverthe-
less, research on long-term BP treatment is certainly 
warranted since structural-level benefits of BPs could 
potentially be overridden with time (26).
Recombinant human parathyroid hormone peptide 
1-34: teriparatide (TPT)
The effects of PTH on the skeleton are complex and 
differ between states of elevated endogenous and exog-
enous administration of PTH.
The amino-terminal fragment of human parathy-
roid hormone (PTH 1-34), also known as teripara-
tide (recombinant DNA origin), has an anabolic effect 
on bone if administrated intermittently serving as a 
bone-forming agent for the treatment of osteoporosis. 
A daily subcutaneous injection of teriparatide (TPT) 
produces a rapid increase in markers of bone forma-
tion, followed by a more delayed increase in markers 
of bone resorption. It also significantly increases BMD 
measured by DXA reducing the risk of new vertebral 
and nonvertebral fractures by 65% and 53%, respective-
ly, in postmenopausal women with osteoporosis. That 
increase in BMD accounts for no more than 40% of 
its anti-fracture efficacy, suggesting that TPT can also 
modify bone quality (32).
Improvement in both trabecular and cortical bone 
microarchitecture has been suggested in patients using 
TPT. To elucidate these issues, investigations have been 
conducted to evaluate whether changes in BMD cor-
relate with bone structural improvements observed in 
patients treated with TPT.
Bone turnover
Assessment with bone histomorphometry (33) has 
shown that TPT changes bone remodeling by increas-
ing bone formation rates and turnover, securing a large 
number of active bone multicellular units (BMUs) lay-
ing down new bone. Stimulation of bone remodeling 
by TPT at both cancellous and endosteal surface reach-
es a maximum after 6 months of treatment. Subse-
quently, bone turnover returns toward levels measured 
in untreated postmenopausal women, with formation 
still exceeding resorption. In addition, there is direct 
evidence that 12 to 24-months TPT therapy induce 
modeling bone formation at quiescent surfaces (34). 
These mechanisms may contribute to the improvement 
of trabecular and cortical architecture seen after TPT 
treatment.
Microarchitecture and geometry
TPT treatment stimulates both trabecular and cortical 
bone formation, resulting in increased cancellous bone 
volume and cortical thickness (35). There is also some 
evidence for increased periosteal bone apposition, lead-
ing to a gain in bone size (36). Thus, to assess modifica-
tions on cortical bone of postmenopausal women with 
osteoporosis receiving TPT therapy, a cross-sectional 
study estimated parameters of cortical bone quality by 
peripheral QCT in their nondominant distal radius. 
Compared with placebo, patients under TPT had sig-
nificantly higher total bone mineral content, total and 
cortical bone areas, periosteal and endocortical circum-
ferences (37).
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However, cortical porosity in patients with hyper-
parathyroidism has raised the concern that intermittent 
PTH given to treat osteoporotic patients may weaken 
cortical bone by increasing its porosity. To evaluate this 
potential effect of TPT therapy, Burr and cols. (38) treat-
ed ovariectomized monkeys for up to 18 months with 
TPT and observed increased dose-dependent intracorti-
cal porosity in their humerus without a significant effect 
on bone strength. Most porosity was concentrated near 
the endocortical surface where its mechanical effect is 
small. Further, Sato and cols. (39) conducted a detailed 
quantitative analysis of the effects of TPT on the proxi-
mal femur of ovariectomized monkeys and concluded 
that TPT had beneficial effects on the proximal femur 
despite increasing cortical porosity. Cortical porosity 
did not adversely affect the mechanical integrity of the 
proximal femur because enhanced cortical area (prob-
ably due to increased periosteal bone apposition) and 
trabecular bone volume more than compensated for the 
porosity. Of note, much of the beneficial effects of TPT 
were retained 6 months after treatment.
Mineralization
Misof and cols. (40) have evaluated BMD distribution 
of iliac crest bone biopsies before and after TPT treat-
ment for 18-36 months in men and women with os-
teoporosis using qBEI. In cortical bone, pairwise com-
parison of biopsies before and after treatment revealed 
a reduction in the typical calcium concentration in men 
but no change in women, with an increase in the het-
erogeneity of mineralization in both. In cancellous bone, 
there was no change in the typical calcium concentra-
tion, but there was a greater heterogeneity of mineral-
ization in both men and women due to newly formed 
bone matrix. Small angle X-ray scattering performed on 
a subgroup of subjects revealed normal collagen/min-
eral structure. These findings confirm the observations 
that PTH stimulates skeletal remodeling, resulting in 
an increased percentage of newly formed bone matrix 
of lower mineral density.
Collagen and microdamage
Garnero and cols. (41) have studied the effects of PTH 
(1-84) and alendronate (ALN) on urinary αα/ββ CTx 
ratio in postmenopausal women with osteoporosis. 
During the first year, there was no significant change 
in the αα/ββ CTx ratio with PTH or ALN treatment, 
suggesting that type I collagen degradation products 
excreted in the urine during the first year of PTH may 
arise predominantly from resting bone that was formed 
before initiating therapy. Alternatively, isomerization of 
collagen formed during PTH treatment reached equi-
librium before being degraded. At 24 months, howev-
er, there was a marked increase in the αα/ββ CTx ratio 
in women who had received PTH during the first year 
followed by a second year of placebo or ALN whereas 
the ratio only slightly increased after 2 yr of continu-
ous ALN, suggesting that PTH therapy may result in 
decreased bone collagen maturation. The authors con-
clude that treatment with PTH (1-84) for 1 yr followed 
by 1 yr of placebo or ALN may be associated with de-
creased type I collagen isomerization. The influence of 
these biochemical changes of type I collagen on bone 
fracture resistance remains to be studied.
Analogous results were obtained previously by Pas-
chalis and cols. (42) analyzing bone biopsies from pa-
tients following placebo or TPT. In the TPT group, 
a trend towards an increase in divalent crosslinks was 
observed after treatment, corresponding to increased 
formation of newly synthesized collagen.
Suppression of bone turnover by BPs is associ-
ated with increased bone microdamage accumulation 
in animal models but effects of TPT on microdamage 
accumulation had not been reported. Hence Dobnig 
and cols. (43) have studied the effect of increased bone 
turnover and improved bone structure on microdam-
age accumulation in 66 postmenopausal women with 
osteoporosis who started with TPT (20 µg/d) as first 
treatment (38 women) and in those who switched 
from long-term ALN (10 mg/d or 70 mg/wk) to TPT 
treatment (28 women). Iliac crest bone biopsies were 
collected and analyzed for microstructure and micro-
damage accumulation at baseline and after 24 months 
of TPT administration.
TPT treatment reduced microdamage accumulation 
in osteoporotic patients who had been previously treat-
ed with ALN and reduced crack length regardless of 
prior treatment. Moreover the authors highlighted that 
an intact microarchitecture is essential for maintaining 
microdamage accumulation at physiologically normal 
levels in osteoporotic patients.
Strontium ranelate (SR)
Strontium ranelate (SR) is an oral antiosteoporotic 
drug that promotes bone formation in vitro by enhanc-
ing pre-osteoblastic cell replication, increasing osteo-
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blastic differentiation and raising the osteoprotegerin/
RANK-L ratio. Aside from these effects on osteoblasts, 
SR decreases bone resorption by inhibiting osteoclast 
activity and osteoclastic differentiation (44). Recent 
studies have shown that the activation of osteoblast 
replication is partly mediated by the calcium sensing re-
ceptor (CaR) which is also involved in the SR-induced 
osteoclast apoptosis (45).
Because strontium is a heavier element than calci-
um, its incorporation into bone influences BMD mea-
surements. In addition, it has been shown that SR is 
distributed in calcified matrix and is easily exchange-
able from bone mineral, being slightly linked to mature 
crystals through ionic substitution. The combined ef-
fects of strontium distribution in bone and increased 
X-ray absorption of strontium compared with calcium 
lead to amplification of BMD measurement by DXA. 
These effects account for approximately 50% of the 
measured changes in BMD. However, an algorithm for 
adjustment of BMD involves a number of assumptions 
and cannot be used for individual patients (46). Over-
all, BMD changes in patients treated with SR account 
for 75% of the reduction in fracture risk suggesting that 
this therapy also interferes on bone quality (45).
Microarchitecture and geometry
In vivo studies indicate that SR decreases bone resorp-
tion and promotes bone formation, preventing bone 
loss. This positive uncoupling between bone formation 
and resorption results in bone gain and improvements 
in bone geometry and microarchitecture in growing 
animals. When administered to female rats during 2 
years, SR induced a dose-dependent increase in bone 
mechanical properties at the level of the vertebral body 
and midshaft femur (47). In addition, treatment with 
SR prevents the deleterious effect of ovariectomy on 
bone strength. After one year of exposure to SR, bone 
mechanical properties of vertebrae of ovariectomized 
rats were significantly preserved in association with a 
partial preservation of the trabecular microarchitecture: 
a dose-dependent effect on the bone volume/trabecular 
volume ratio and trabecular number and thickness (48).
Iliac crest bone biopsies of postmenopausal osteopo-
rotic women analyzed by 3D µCT have demonstrated 
some improvement of both trabecular and cortical bone 
microstructure after 3 years of treatment with SR. In 
comparison to placebo, patients treated with SR for 3 
years showed significant increase in the number of tra-
beculae (+14%), decrease of trabecular separation (-16%) 
and increase in cortical thickness (+18%). Furthermore, 
a significant decrease (-22%) of the model index struc-
ture suggested a shift in trabecular structure from rod-
like to plate-like configuration resulting in stronger 
bone. These changes in trabecular and cortical structure 
may explain the anti fracture efficacy of SR (49).
Mineralization
Boivin and cols. reported histomorphometric evalua-
tion of osteoporotic women treated with SR and found 
no effect on crystal characteristics or mean degree of 
mineralization of bone (MDMB) over a large range of 
doses (0.5, 1, and 2 g/d) (30).
Estrogens: hormonal replacement therapy (HRT)
The Women’s Health Initiative (WHI) demonstrated 
the effect of hormone therapy on BMD and on osteo-
porotic fracture reduction at several sites, including 
the hip. Even though the benefits of postmenopausal 
hormone replacement therapy (HRT) on fracture were 
clear, adverse effects such as increased risk of stroke and 
deep vein thrombosis were concerning, aggravated by 
later findings of increased risk of breast cancer and lack 
of cardio-protective benefits (50). For these reasons, in 
spite of its effectiveness for preventing postmenopausal 
osteoporosis, HRT should only be considered in wom-
en at significant risk of osteoporosis who cannot take 
non-estrogenic medications.
Bone turnover and microarchitecture
HRT is an effective prophylactic treatment for early 
postmenopausal bone loss since it reduces bone re-
modeling, which may be accelerated by progressive 
osteoclastic hyperactivity. Besides, estrogens are also 
capable of exerting an anabolic effect in women with 
osteoporosis, even when started well into menopause as 
shown by Khastgir and cols. (51). Histomorphometric 
studies of iliac bone biopsies performed on 22 older 
postmenopausal females with low BMD, before and 
6 yr after HRT, revealed BMD improvement at both 
lumbar spine and proximal femur sites. Furthermore, 
they observed an increase in cancellous bone volume 
and an increment of wall thickness after 6 yr of HRT, 
indicating net bone gain.
The investigation of estrogenic actions on the skel-
eton has mainly focused on cancellous bone. To in-
vestigate the effects of both conventional HRT and 
high-dose estradiol on cortical bone in postmenopausal 
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women, Vedi and cols. (52) conducted histomorpho-
metric studies plus image analysis of the iliac bone at 
baseline and 2 yr after HRT. High-dose estrogen-treat-
ed women showed the highest cortical width while the 
proportion of canals with an eroded surface was signifi-
cantly lower than in women before or after conventional 
HRT. Their bone formation rate was significantly lower 
than in untreated women and intermediate values were 
found in women treated with conventional HRT. These 
results provided evidence that estrogen induces sup-
pression of bone turnover in iliac crest cortical bone of 
postmenopausal women, in a dose-dependent manner.
Mineralization and collagen
To assess whether HRT modifies the degree of bone 
mineralization and collagen cross-linking, Paschalis and 
cols. (53) analyzed bone samples from early postmeno-
pausal women at baseline and 2 years after HRT by a 
combination of hystomorphometric and infrared im-
aging techniques. They observed a shift in the degree 
of bone mineralization and collagen cross-links ratio 
(PYD/DPD ratio) toward higher values after HRT, 
suggesting that the bone was more mature, as might be 
expected from suppressed osteoclastic activity.
Selective estrogen receptor modulators (SERMs)
During the past decade, considerable attention has been 
focused on SERMs as an alternative to postmenopausal 
estrogen therapy. These agents act as estrogen agonists 
in some tissues and antagonists in others due to their 
specific actions on estrogen receptors. Benefits with ral-
oxifene (a nonsteroidal SERM) therapy arose from the 
MORE (Multiple Outcomes of Raloxifene Evaluation) 
trial, in which 7705 postmenopausal women with os-
teoporosis were studied. BMD increased in the spine 
and femoral neck and the risk of vertebral fractures was 
significantly reduced, without any significant effect on 
non-vertebral fractures. The risk of endometrial hy-
perplasia was unaltered and the risk of invasive breast 
cancer was significantly reduced while there was an in-
creased risk of venous thromboembolism (54). Even 
though the risk of coronary events was unaltered by 
therapy, LDL cholesterol levels were reduced and HDL 
levels were raised.
Only 4%-5% of the fracture reduction observed with 
raloxifene (RLX) results from increments in lumbar 
spine or femoral neck BMD, suggesting that RLX may 
also improve bone matrix properties (55).
Bone turnover
To compare raloxifene therapy to HRT, Weinstein and 
cols. (56) analyzed the impact of these drugs on bone 
turnover after one year of treatment. The frequency of 
remodeling events on cancellous bone and rate of bone 
formation in both cancellous and endocortical bone 
increased in the placebo group, while these measure-
ments decreased in both drug treatment groups. BMD 
increased from baseline at the lumbar spine (in the HRT 
group) and in the total body (for both RLX and HRT). 
Compared with RLX group, the increase in BMD was 
greater in the HRT group at the lumbar spine but not 
in the total body. Bone markers significantly decreased 
in both active treatment groups, changes significantly 
different from those seen with placebo. Overall, the 
authors suggest that RLX preserves bone mass by re-
ducing the elevated bone turnover found in postmeno-
pausal women by mechanisms similar to those operative 
in postmenopausal women receiving HRT.
Microarchitecture and geometry
Although there are similarities between raloxifene and 
BPs in preventing decreases in maximal load, bone 
mass, and microarchitecture in ovariectomized rats, the 
raise in BMD is more pronounced after BP than RLX 
(57). This finding parallels observations from canine 
studies that showed a significant improvement of the 
mechanical properties at the material level after 1-year 
treatment with raloxifene even if aBMD, vBMD, BV/
TV, and percent ash remained unaltered in comparison 
with control. These material-level improvements have 
been detected at both cortical and trabecular bone sites.
In the clinical setting, a relatively mild effect of 
RLX on BMD has also been observed despite a very 
noteworthy vertebrae antifracture efficacy. The ob-
served improvements in microarchitecture may, at least 
in part, underlie the ability of RLX to increase bone 
strength and reduce fracture risk, yet it seems that the 
substantial beneficial action on intrinsic bone material 
quality, both at the cortical and trabecular level, plays 
an important role in the mechanism by which this agent 
is effective in osteoporosis treatment. In addition, it 
should also be noted that SERMs are known to have a 
protective effect on osteocytes in vitro; however, there 
is no convincing evidence of this effect in humans (57).
Mineralization
The effects of RLX treatment (60 x 120 mg/d) on 
mean degree of mineralization of bone (MDMB) were 
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also investigated in a prospective longitudinal study of a 
subset of 64 patients enrolled in the MORE trial. Quan-
titative microradiography analysis of iliac crest biopsies 
taken at baseline and after 2 years of treatment revealed 
a significant dose-dependent increase on MDMB com-
pared with baseline. The observed increase in mineral 
content with preserved heterogeneity of mineral distri-
bution is a result of the ability of RLX to decrease bone 
turnover, therefore extending the duration of second-
ary mineralization of bone basic structural units (BSUs) 
and allowing new bone to achieve a higher degree of 
mineralization. This mechanism has been shown to im-
prove the biomechanical properties of bone and should 
contribute to the reduction in fracture risk observed af-
ter treatment with RLX. On the other hand, increased 
skeletal mineral can improve structural rigidity and too 
much mineral may lead to an increase in brittleness (58).
Collagen and microdamage
It has been hypothesized that RLX may alter the or-
ganic matrix (26) and, in particular, collagen, which is 
known to contribute to the biomechanical and intrinsic 
properties of bone. To answer this question, Byrjalsen 
and cols. (11) evaluated the effect of different anti-re-
sorptive treatments (BPs, HTR and RLX) on bone col-
lagen maturation measured by the αα/ββ CTx ratio. 
It was found that these anti-resorptive therapies induce 
differences in the maturation profile of bone collagen, 
i. e. αα/ββ CTx ratio is greater after treatment with 
HRT than RLX whereas αα/ββ CTx ratio after RLX 
therapy is greater than BPs.
There is considerable debate on defining normal re-
modeling rate and the potential deleterious effects of 
an excessive suppression by antiresorptive agents, given 
the potential impairment on microdamage repair and 
on the replacement of old bone by fresh new units. 
Although no fracture data support this highly contro-
versial theory, SERMs do not suppress bone turnover 
to an extent that would cause such concerns. In fact, 
the data show that RLX restores bone turnover to pre-
menopausal levels (59) and experimental data demon-
strate that the drug actually reduces microcrack density 
in bone tissue.
Calcitonin (CTN)
Calcitonin (CTN) is an endogenous polypeptide hor-
mone secreted by thyroid C cells that inhibits bone 
resorption by osteoclasts. Nevertheless, there is also 
concern that prolonged exposure to CTN may down-
regulate calcitonin receptors on osteoclasts, which 
could allow the osteoclasts to recover from the sup-
pressive action of CTN. Its intermittent administration 
has been recommended as a strategy to avoid clinical 
resistance (60).
A number of randomized trials have suggested that 
injectable or intranasal salmon CTN is effective in pre-
vention of trabecular bone loss in late menopause. One 
classical trial evaluated intranasal administration of 200 
IU of calcitonin and showed a vertebral fracture reduc-
tion of 33-36% without substantial effects on BMD 
(61). A 30% reduction in hip fracture was observed by 
Kanis in patients treated with injectable CTN but data 
with usual doses of nasal CTN in nonvertebral sites are 
controversial. In addition, CTN may have an analgesic 
effect in women with acute vertebral fractures, which 
appears to be independent of its effect on osteoclastic 
resorption (60).
Clinical studies addressing the effects of CTN on 
bone quality are scarce but at least one should be point-
ed out. The authors postulated that CTN therapy may 
be associated with improvements in bone microstructure 
that are not detected by BMD. To address this hypoth-
esis, a 2-year randomized placebo-controlled study 
of daily dose of 200 IU salmon calcitonin nasal spray 
(CT-NS) was carried out including approximately 45 
postmenopausal osteoporotic women per group, using 
the noninvasive MRI technology at multiple skeletal 
sites and µCT/histomorphometry from iliac crest bone 
biopsies to assess trabecular microarchitecture (10).
MRI assessment of distal radius and lower trochan-
ter of the hip revealed preservation of parameters of tra-
becular microarchitecture in the CT-NS group, where-
as significant deterioration was observed in the placebo 
group. Combined µCT/histomorphometric analysis of 
iliac crest bone biopsies as well as BMD measured by 
DXA did not reveal consistent differences in architec-
ture between CT-NS and placebo groups.
In conclusion, the QUEST study results suggested 
therapeutic benefits of CT-NS in maintaining trabecu-
lar microarchitecture at multiple skeletal sites and sup-
ported the use of MRI technology in clinical research 
trials for assessing bone microstructure. Nevertheless, 
the results also highlighted site-specific differences in 
the response to antiresorptive therapies and the impor-
tance of sufficiently large sampling volumes to obtain 
reliable assessment of bone architecture (10).
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SUMMARY AND CONCLUSIONS
Despite genuine advance, therapy for osteoporosis still 
represents a considerable research challenge. BMD is a 
useful clinical tool for diagnosing and monitoring os-
teoporosis but has limitations that need to be recog-
nized and addressed. Since drugs and bone disorders 
have a spectrum of effects ranging from the microscop-
ic to the macroscopic level (Table 1) that may change 
depending on the underlying physiology of a particular 
patient and BMD may not detect all anticipated effects.
Bone turnover markers may be a useful comple-
ment for solving this puzzle as they reveal effects on 
bone remodeling in the absence of changes on bone 
density tests. Unfortunately, no monitoring technique 
is absolutely accurate. Future prospects for in vivo bone 
strength analysis using CT or MRI have yet to be de-
veloped to the point of clinical utility, but this may well 
be the way of the future. Finite element analyses can 
reproduce 3D constructs of bone through noninva-
sive measurements, congregating all elements of bone 
strength into a useful clinical tool for assessing thera-
peutic response (62).
Up to now, the main effects of osteoporosis medi-
cations on bone quality can be summarized as follow. 
Antiresorptive therapy, specially the bisphosphonates, 
generally increases MDMB and homogeneity of miner-
alization. It is suggested that most of the change in the 
aBMD induced by antiresorptive therapies results from 
the increase in the MDMB.
The effects of antiresorptive therapy on cortical bone 
are limited, but suggestive of little impact on size albeit 
decreased porosity. The relatively modest changes in 
aBMD despite dramatic decreases in antifracture effica-
cy observed in antiresorptive trials may be at least par-
tially a consequence of reduced bone remodeling which 
leads to an increase in bone mass and to a decrease in 
the number of trabecular stress-risers.
On the other hand, TPT has been shown to in-
crease trabecular thickness and bone turnover; however, 
because of its anabolic properties, it results in net bone 
gain, perhaps explaining some of its positive impact on 
fracture risk. Despite a dramatic increase in bone mass, 
the mineralization is actually decreased and the net re-
sult is a greater aBMD following therapy. Strontium 
ranelate, however, induces a falsely elevated aBMD as a 
result of its incorporation into the apatite.
Regarding microdamage, microcrack accumulation 
was observed in bone treated with BPs but its presence, 
induced by other drugs used in osteoporosis therapy, 
was not confirmed. In any case, therapeutic doses of 
BPs do not negatively impact on the accumulation of 
microcracks to a level that would increase fracture sus-
ceptibility in humans.
The future goal for fracture risk assessment is the 
development of a virtual biopsy to assess the material 
and structural properties of bone at clinically important 
sites simultaneously and noninvasively (30).
Table 1. Factors that determine bone quality categorized by physical scale 
Scale Bone characteristics
> 10-3 m Bone size and bone shape
Bone density spatial distribution
10-6-10-3 m Microarchitecture
Porosity
Cortical shell thickness
Lacunar number/morphology
Remodeling cavity number, size and distribution
10-9-10-6 m Mineral and collagen distribution/alignment
Microdamage type, amount and distribution
< 10-9 m Collagen structure and cross-linking
Mineral type and crystal aligment
Collagen-mineral interfaces
Adapted from Hernandez et al., 2006 (65).
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